Page 3 - மேம்படுத்துகிறது உலகளாவிய ஔட்கம்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 10, 2021 May 10, 2021 11:00 UTC Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care 1 FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint 1,2,3 Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared to the FIDELIO-DKD stu

United statesUnited kingdomLuism ruilopeBayer crossChristian rommelHead of researchBritish medical journal open diabetes researchDrug administrationPreventative medicine departmentInternational diabetes foundationPublic healthAutonoma universityKidney fundNational kidney foundationAmerican society of nephrologyInternational diabetes federation